Clinical Trial Update: Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is studying CD19 CAR-T cell therapy for refractory systemic sclerosis (scleroderma). The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: The Children's Hospital of Zhejiang University School of Medicine | Conditions: Systemic Sclerosis (SSc) | Phase 1 | Status: RECRUITING